coronary stenting is a percutaneous procedure intended to regain coronary artery patency overcoming the major limitations of balloon angioplasty: acute recoil and negative vessel remodelling.
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The first contemporary balloon-expandable stent was the Palmaz, immediately followed by an articulated variant known as the Palmaz-schatz, the first stent to be tested in large multicentre trials (the stent restenosis study [sTress] and the Belgium-netherlands stent [BenesTenT] ). [4] [5] [6] however, initial stent designs were large, rigid devices that made implantation difficult. in addition, these stents were crimped by hand in the balloon catheter, resulting in precarious safety of the device inside the implantation system. 5, 6 As a consequence, pre-dilatation of the target lesion used to be routine prior to stent deployment. While percutaneous treatment of coronary artery disease with stent implantation is associated with high rates of clinical success and low rates of procedural morbidity, the risks of exposure to radiation, administration of contrast dye, haemorrhaging at the access location and cost are not insignificant. These risks of percutaneous coronary intervention (Pci) are incrementally greater in older patients, disease in multiple vessels that require phased procedures, chronic kidney disease and peripheral arterial disease, The recently developed Acrobat stent-on-a-Wire (soAW) coronary stent system (svelte™ Medical systems) is a coronary stent system that uses a fixed-wire catheter platform. The system combines a very thin (81µm) cobalt-chromium (L605) stent mounted on a delivery system with a 0.012-inch integrated guidewire tip (distance from the tip of the wire to the stent is 22mm; see Figure 1 ). Besides the facility to directly deploy the stent, this novel device should also potentially facilitate treatment of small vessels and distal lesions. The current publication addresses in more details the Acrobat soAW system.
Description of the Device
The svelte™ Acrobat soAW coronary stent system consists of a balloon-expandable stent pre-mounted on svelte's soAW single-lumen fixed-wire implantation catheter platform. The stent is made of cobalt-chromium alloy (L-605) and is available in diameters ranging from 2.5 to 4mm and lengths of 8 to 28mm. The Acrobat soAW system is compatible with 5 french (fr) guiding catheters (minimum internal diameter 0.056 inches).
The lesion entry profile of the formable radiopaque wire tip is 0.012 inches (see Figure 2 ). The soAW implantation catheter's operational extension is 145cm, and includes two proximal axis markers ( The basic steps to deploy the Acrobat soAW coronary stent system are represented in Figure 4 . This innovative stent system was recently evaluated in a first-in-man (fiM) study. The svelte fiM trial was a multicentre (four sites), international (Brazil, The netherlands and colombia), prospective, non-randomised, single-arm registry of the novel Acrobat soAW for the treatment of de novo coronary lesions. A total of 46 patients were enrolled with planned angiographic evaluation at six months. for a pre-specified cohort of 15 patients, serial intravascular ultrasound (iVus) assessments right after stent implantation and at six months will be performed while for a cohort of 19 patients, optical coherence tomography (ocT) assessment at similar time points will be performed. The primary end-point of the study is the survival-free rate of combined major adverse cardiac events (MAce; cardiac death, myocardium infarction and target-lesion revascularisation) at 30 days. As secondary end-points it will analyse the following: device success rate; lesion success rate; procedure success rate; (individual) incidence of cardiac death, myocardium infarction and target-lesion revascularisation; binary restenosis and in-stent/in-segment late luminal loss at six months; stent thrombosis rate (according to Arc definition) up to six months. 
Conclusions
The svelte™ Acrobat soAW has the potential to significantly improve All content in this publication is the sole property of Touch Group plc. Touch Group plc cannot guarantee the accuracy, adequacy or completeness of any information contained therein, and cannot be held responsible for any errors or omissions, or for the results obtained from the use thereof. Where opinion is expressed, it is that of the author(s) and does not necessarily coincide with the editorial views of Touch Group plc.
